Tumor necrosis factors are a group of cytokines that are secreted by macrophages and may induce cell death of certain tumor cell lines, which leads to inflammation. TNF inhibitors are the drug that stops inflammation. They are mainly indicated for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, anklyosing Spondilitis They are also called TNF blockers. Currently only five TNF are approved which include humira (adalimumab), remicade (infliximab), cimzia (Certolizumab pegol), enbrel (etanercept), and simponi (golimumab). Humira is the king and bestselling drug of the century due to high clinical efficacy and is approved for multiple indications. Entry of biosimilar in the market, major patent expiry of blockbuster drug, and strong ongoing clinical pipeline of biosimilar has boosted the growth of TNF biosimilar market. Moreover, the rising incidence and prevalence of rheumatic disease and switching trends from traditional treatment to biologic therapy have increased the growth of the market. However, stringent government regulation and entry of other promising therapy in the market hamper the growth of the market.
The global TNF biosimilar market is segmented by drug, distribution channel, and geography. On the basis of treatment the global market is further sub segmented into adalimumab biosimilar, infliximab biosimilar, certolizumab biosimilar, etanercept biosimilar, and golimumab biosimilar. Infliximab biosimilar segment followed by etanercept biosimilar segment is expected to hold significant share of the market due to early patent expiry and entry of biosimilars like erie Etanercept-szzs and Infliximab-dyyb into the major market like Europe and United States. Humira is protected with more than 100 patents in US which make the entry of biosimilars complicated in the US market however, biosimilar of adalimumab is expected to launch in the US by 2023 and in Europe in 2018 which drives the growth of the market during forecast period. TNF Inhibitors market is already saturated thus certolizumab biosimilar and golimumab biosimilar segments are expected to hold minimal share of the market due to late entry of biosimilars in the market. On the basis of distribution channel the global market is segmented into online pharmacy, hospital pharmacy, and retail pharmacy. Hospital pharmacy segment dominates the global market followed by retail pharmacy and online pharmacy. Online pharmacy segment is expected to grow at high CAGR due to the increase in number internet user and ease of use.
At regional level, the global TNF biosimilar market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. In terms of revenue, Europe followed by North America is major contributor for the global TNF biosimilar market. This is because strong ongoing clinical pipeline of biosimilars, increasing research and drug development activities, presence of major players, and increase in demand for biosimilars propels the growth of the market in the region. Asia Pacific is the third promising revenue contributor which is expected to grow at a rapid pace in upcoming year. Countries such as Japan, India, and China are major contributors to this market. Emerging and colossal population base countries such as China and India offer tremendous market opportunities for the TNF biosimilar market. Entry of biosimilar will increase patient affordability and accessibility which in turn increase in consumption of TNF in low-income countries.
Some of the market players leading the global TNF biosimilars market include Amgen, Sandoz, Boehringer Ingelheim, Pfizer, Samsung Bioepis, Coherus Biosciences, Celltrion, Nichi-Iko, and other prominent players.
